Twelve Extra Hours
Disc Medicine says bitopertin met both goals in a phase 3 trial for a rare sunlight disease: 41.4 percent less protoporphyrin, and 12.2 more hours a month in light without pain. The FDA refused the drug once already.
A pill for the sunlight disease hit both targets. The FDA already said no once.
Erythropoietic protoporphyria makes sunlight painful. A substance called protoporphyrin IX builds up in the blood, and the skin burns after minutes outside. The only US-approved treatment is Scenesse, an implant. On 19 October Disc Medicine said its pill, bitopertin, met both co-primary endpoints in the phase 3 APOLLO trial. Whole-blood metal-free PPIX fell 41.4 percent versus placebo. In month 6, patients spent 12.2 more hours in light without pain than the placebo group. The company said the treated analysis included patients aged 12 and older, that every secondary endpoint was also met, and that it will resubmit a new-drug application by the end of 2026.
The FDA refused this drug earlier in 2026. The agency said the company had not shown a clear link between lower PPIX and more time in the sun. APOLLO is the company's answer. It is a sponsor topline, filed with the SEC, not a journal paper.
This is a rapid-fire number, not a second health segment. The episode's health story is the body-clock paper.
Key Facts
- Disease: erythropoietic protoporphyria, including X-linked protoporphyria
- APOLLO phase 3: bitopertin versus placebo
- PPIX: minus 41.4 percent versus placebo (p less than 0.0001)
- Time in light without pain, month 6: plus 12.2 hours versus placebo (p=0.0010)
- FDA refused approval earlier in 2026; resubmission planned by the end of 2026
- Existing approved option: Scenesse implant
- Source: Disc Medicine EX-99.1, 19 October 2026; Reuters the same day
Why This Matters
For a person who plans the day around shade, 12 extra hours a month in the light is a school sports afternoon or a walk to the car. It is not a cure, and it is not yet a prescription.
What We Don't Know Yet
Peer review. A journal has not published APOLLO. The FDA already declined this drug once. "Generally well tolerated, no new safety concerns" is the company's sentence. Avoiding sun remains the main management until a regulator says otherwise.